Navigation Links
Platelet-rich plasma therapy a safe option for cartilage damage, new study finds
Date:7/13/2012

BALTIMORE, MD When it comes to treating cartilage tears in athletes, Platelet Rich Plasma (PRP) therapy is a safe and effective method of treatment, according to research presented today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in Baltimore.

"Using PRP therapy to repair cartilage is still relatively experimental, but studies like this show it's not only safe but also offers a significant improvement in function and quality of life for patients," said Elizaveta Kon, MD, lead author for the study and Director of Nano-Biotecnology Laboratory at the Rizzoli Orthopaedic Institute in Bologna, Italy. "None of the patients treated experienced complications like infection, deep vein thrombosis or fever."

During the study, 180 patients were treated for chronic pain or swelling of the knee with either PRP therapy or viscosupplementation, a more common hyaluronic acid-based treatment for cartilage damage. A total of 109 patients, with an average age of 56, reached a final evaluation. Both treatment groups demonstrated significant improvement based on higher post-treatment IKDC scores, which measure pain and basic function in follow-up interviews.

"As athletic participation has grown," Kon noted, "new problems like cartilage lesions, or tears, continue to emerge. Finding the right approach to treatment is difficult, but PRP has emerged as a viable option according to our research."

Kon also noted that long-term follow-ups for PRP treatments are needed to further evaluate the overall effectiveness of the therapy for future patients.


'/>"/>

Contact: Lisa Weisenberger
lisa@aossm.org
847-655-8647
American Orthopaedic Society for Sports Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Therapy exploits addiction of leukemia cells
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. 19th century therapy for Parkinsons disease may help patients today
10. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted February 8, 2016 ... Awards. , Awards include the Information Security Executive® of the Year, ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... N.J. , Feb. 8, 2016  Otsuka Pharmaceutical ... announced that they have entered into a licensing agreement ... in the U.S. and Puerto Rico ... a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new ... --> In a Phase II clinical ...
(Date:2/8/2016)... LAWRENCEVILLE, N.J. , Feb. 8, 2016   ... for healthcare professionals to guide them through GS1 Standards ... and Drug Administration (FDA) Unique Device Identification (UDI) rule. ... standards, GS1 US; Beth Gibson , senior director ... Roberts , industry development director, GS1 US ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
Breaking Medicine Technology: